These analyses suggested that TP53 mutations in patients with osteosarcoma predicted poor 2-year overall survival, whereas more clinical studies should be conducted taking into account the age, sex, metastasis, histological grades, primary sites, and treatment of osteosarcoma patients. The gene discussed is TP53; the disease is osteosarcoma.